Hu Hiroe, Tillman Alaina N, Fujita Miyu, Yoshikawa Mayu, Ballard Elizabeth D, Lee Yoojin, Zarate Carlos A
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, NIMH-NIH, 10 Center Drive, Bldg. 10, Room 7-5545, Bethesda, MD 20892, USA.
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, NIMH-NIH, 10 Center Drive, Bldg. 10, Room 7-5545, Bethesda, MD 20892, USA.
Psychiatry Res. 2025 Jul;349:116513. doi: 10.1016/j.psychres.2025.116513. Epub 2025 Apr 25.
Subanesthetic-dose ketamine has recently been reported to improve hedonic pleasures associated with social interactions and altruism in individuals with treatment-resistant depression. However, whether ketamine-among other glutamate receptor modulators-also improves empathy and/or prosocial behavior in humans remains unknown. Under a framework grounded in neurobiology that proposes that prosocial behavior is preceded by empathy, this systematic review sought to: (1) explore the entactogenic effects of glutamate receptor modulators observed in clinical trials (as either primary or secondary outcomes), and (2) synthesize the findings regarding which glutamate receptor modulators produce entactogenic effects. Thirty studies that included self-reported ratings, neuroimaging, and/or behavioral task outcomes met inclusion criteria suggesting potential entactogenic effects associated with ketamine and, to less convincing extent, d-cycloserine (DCS). The findings suggest that ketamine and DCS may modulate self- and other-perception, involving changes in activity in brain regions involved in empathetic concerns and mentalizing, the ability to understand one's own and others' thoughts and feelings. These findings may guide potential therapeutic interventions for neuropsychiatric conditions associated with impaired empathy and prosocial behavior, including mood disorders, neurodevelopmental disorders, psychotic disorders, and personality disorders.
近期有报道称,亚麻醉剂量的氯胺酮可改善难治性抑郁症患者与社交互动及利他行为相关的享乐体验。然而,氯胺酮以及其他谷氨酸受体调节剂是否也能改善人类的同理心和/或亲社会行为仍不明确。在一个基于神经生物学的框架下,该框架提出亲社会行为之前存在同理心,本系统综述旨在:(1)探索在临床试验中观察到的谷氨酸受体调节剂的致幻效果(作为主要或次要结果),以及(2)综合关于哪些谷氨酸受体调节剂产生致幻效果的研究结果。三十项纳入了自我报告评分、神经影像学和/或行为任务结果的研究符合纳入标准,提示与氯胺酮以及程度稍弱的d -环丝氨酸(DCS)相关的潜在致幻效果。研究结果表明,氯胺酮和DCS可能调节自我认知和对他人的认知,涉及与同理心关注和心理化相关的脑区活动变化,心理化是理解自己和他人思想及感受的能力。这些发现可能为与同理心和亲社会行为受损相关的神经精神疾病,包括情绪障碍、神经发育障碍、精神疾病和人格障碍,指导潜在的治疗干预。